Arrowhead Directors Sell $1.19M Ahead of Key Heart Data
Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in shares on August 18, days before a 750-patient cardiovascular dataset is due at a late-breaking conference session. The company
Arrowhead Directors Sell $1.19M Ahead of Key Heart Data
NEW YORK, August 30 —
Arrowhead Pharmaceuticals, Inc. (ARWR) has a 750-patient cardiovascular dataset landing at a late-breaking conference session, the kind of slot reserved for trial-defining results. Two directors chose the week before to sell $1.19 million in shares at $86 to $87. Whether that timing reflects routine diversification or sharper knowledge of what the data shows is precisely what the readout will answer.
- Directors Perry and Olukotun sold a combined $1.19M in shares on August 18; no insider has bought shares in 90 days.
- Analyst consensus target of $110.18 implies 30% upside from the current $84.91 share price.
- Arrowhead posted 171% TTM revenue growth to $670M but generated negative free cash flow of -$49M.
Directors Exit Before Disclosure
Director Michael S. Perry sold 11,600 shares at $87.30 for $1,012,680 on August 18, per his Form 4 filing. Director Adeoye Y. Olukotun sold 2,000 shares at $86.96 the same day for $173,920. Those open-market transactions left insiders holding just 3.7% of outstanding shares against institutional ownership of 85.6%, with zero purchases logged in the trailing 90 days. A 9.1% short interest position reflects existing skepticism. Insiders at a clinical-stage company have access to unblinded trial results; the simultaneous same-day exits, days before a high-profile data presentation, make the conference slot more consequential than routine framing implies.
100% Margins, Zero Products on Market
Arrowhead Pharmaceuticals develops RNA interference therapeutics, molecules that silence disease-causing genes to treat conditions at their molecular root. Its two Phase 3 programs, Plozasiran targeting triglyceride-raising APOC3 and Zodasiran targeting lipid-metabolism regulator ANGPTL3, form the commercial thesis, supported by collaboration agreements with GlaxoSmithKline, Takeda, Amgen, and Sarepta Therapeutics. Trailing revenue of $670 million carries 100% gross margins because those proceeds are milestone and licensing payments, not drug sales. Anyone running a DCF model on Arrowhead is discounting a cash-flow story that does not yet exist: negative free cash flow of -$49 million against $1.60 billion in cash and $1.38 billion in debt.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ARWR | $12.0B | n/a | +230.6% |
| ALNY | $31.7B | 18.8x | -47.0% |
| IONS | $10.1B | n/a | +6.2% |
| AXSM | $10.4B | 39.5x | +61.2% |
| ACAD | $5.0B | 32.7x | +13.3% |
| SRPT | $2.2B | 8.1x | +14.9% |
A Binary Outcome
The conference data is a binary event for the stock's current setup. Positive results with a clean safety profile give the analyst consensus target of $110.18 a credible foundation and frame the insider sales as diversification from a stock that has run. A disappointing readout lands differently on a company whose EPS missed consensus by 10.5% last quarter and whose $11.99 billion market capitalization rests on future regulatory approvals rather than current earnings. The 750-patient late-breaking session is the next checkpoint; the data it discloses will reframe every transaction before it. Run the free Arrowhead Pharmaceuticals, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Arrowhead Pharmaceuticals directors sell shares?
Directors Michael S. Perry and Adeoye Y. Olukotun sold a combined $1.19 million in open-market transactions on August 18, days before a 750-patient cardiovascular dataset is due at a late-breaking conference session. Perry sold 11,600 shares at $87.30 for $1,012,680 and Olukotun sold 2,000 shares at $86.96 for $173,920. No insider has purchased shares in the trailing 90 days.
What is Arrowhead's upcoming cardiovascular data readout?
Arrowhead has a 750-patient dataset scheduled for a late-breaking conference session, the kind of slot reserved for trial-defining results. The company's two Phase 3 programs are Plozasiran, targeting triglyceride-raising APOC3, and Zodasiran, targeting lipid-metabolism regulator ANGPTL3.
What is the analyst price target for Arrowhead Pharmaceuticals?
on future regulatory approvals rather than current earnings, given the company's $11.99 billion market capitalization and negative free cash flow of -$49 million.
Does Arrowhead Pharmaceuticals have products on the market?
Arrowhead does not yet have approved drugs generating product revenue. Its trailing revenue of $670 million comes entirely from milestone and licensing payments, which carry 100% gross margins, while the company holds $1.60 billion in cash against $1.38 billion in debt.
What is Arrowhead's short interest and ownership structure?
Arrowhead carries a 9.1% short interest position, reflecting existing market skepticism. Institutional investors hold 85.6% of outstanding shares, while insiders hold just 3.7%, with zero insider purchases logged over the trailing 90 days.
Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in stock on August 18, days before the company disclosed it will present data from approximately 750 patients at a late-breaking cardiovascular conference session. The simultaneous insider exit and imminent high-profile data readout pose a question the market cannot yet answer: do insiders know something, or are they simply harvesting gains from a stock up 398% on momentum?